Particularly, our analysis highlights that DDI‐H confers a negative prognostic impact on MM patients receiving treatment with BRAF‐i/MEK‐i, highlighted by the highest progressive disease rate. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.